Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-06T06:12:18.575Z Has data issue: false hasContentIssue false
  • English
  • Français

Blood Platelet 5-Hydroxytryptamine Levels in Psychiatric Patients

Published online by Cambridge University Press:  08 February 2018

A. Todrick ,
A. C. Tait  and
Elizabeth F. Marshall
A. Todrick
Affiliation:
From the Department of Clinical Research, Crichton Royal, Dumfries
A. C. Tait
Affiliation:
From the Department of Clinical Research, Crichton Royal, Dumfries
Elizabeth F. Marshall
Affiliation:
From the Department of Clinical Research, Crichton Royal, Dumfries
Get access Rights & Permissions [Opens in a new window]

Extract

The interest of 5-hydroxytryptamine (5HT) for psychiatry arose originally from Gaddum's (8, 9) observation that its peripheral pharmacological actions were antagonized in a highly specific manner by a low concentration of lysergic acid diethylamide (LSD). This led to the hypothesis that the hallucinogenic action of LSD was due to its antagonism to 5HT in the central nervous system (Woolley and Shaw, 21; Gaddum, 7). However, Cerletti and Rothlin (5) subsequently found that brom-LSD, which is not a hallucinogen, was an equally potent antagonist of the peripheral actions of 5HT.

Type
Original Articles
Information
Journal of Mental Science , Volume 106 , Issue 444 , July 1960 , pp. 884 - 890
Copyright
Copyright © Royal College of Psychiatrists, 1960 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Baar, H. S., J. Clin. Path., 1948, 1, 175.Google Scholar
2 Brodie, B. B., Olin, J. S., Kuntzman, R. G., and Shore, P. A., Science, 1957, 125, 1293.Google Scholar
3 Idem , Shore, P. A., and Pletscher, A., ibid., 1956, 123, 992.Google Scholar
4 Idem , Tomich, E. G., Kuntzman, R. G., and Shore, P. A., J. Pharmacol exp. Ther., 1957, 119, 461.Google Scholar
5 Cerletti, A., and Rothlin, E., Nature, London, 1955, 176, 785.Google Scholar
6 Feldstein, A., Hoagland, H., and Freeman, H., J. Nerv. Ment. Dis., 1959, 129, 62.CrossRefGoogle Scholar
7 Gaddum, J. H., in: Ciba Foundation Symposium on Hypertension, 1954. London: J. ' A. Churchill, p. 75.Google Scholar
8 Idem and Hameed, K. A., Brit. J. Pharmacol., 1954, 9, 240.Google Scholar
9 Idem , Hebb, C. O., Silver, A., and Swann, A. A., Quart. J. Exp. Physiol., 1953, 38, 255.Google Scholar
10 Hardisty, R. M., and Stacey, R. S., J. Physiol., 1955, 130, 711.Google Scholar
11 Iidem, Brit. J. Haematol, 1957, 3, 292.Google Scholar
12 Marshall, E. F., Stirling, G. S., Tait, A. C., and Todrick, A., Brit. J. Pharmacol, 1960, 15, 35.Google Scholar
13 Paasonen, M. K., and Vogt, M., J. Physiol., 1956, 131, 617.Google Scholar
14 Pletscher, A., and Bernstein, A., Nature, London, 1958, 181, 1133.Google Scholar
15 Idem , Shore, P. A., and Brodie, B. B., Science, 1955, 122, 374.Google Scholar
16 Iidem, J. Pharmacol exp. Ther., 1956, 116, 84.Google Scholar
17 Pohle, F. J., Amer. J. Med. Sci., 1939, 197, 40.Google Scholar
18 Shore, P. A., Silver, S. L., and Brodie, B. B., Science, 1955, 122, 284.CrossRefGoogle Scholar
19 Udenfriend, S., Weissbach, H., and Clark, C. T., J. biol Chem., 1955, 215, 337.Google Scholar
20 Weiner, M., and Udenfriend, S., Circulation, 1957, 15, 353.CrossRefGoogle Scholar
21 Woolley, D. W., and Shaw, E., Brit. med. J., 1954, ii, 122.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.